Evidence map›Paper›PMID 35338353›Full record

Trial reportProstate cancer and prostatic diseases2022

Serum metabolomic analysis of men on a low-carbohydrate diet for biochemically recurrent prostate cancer reveals the potential role of ketogenesis to slow tumor growth: a secondary analysis of the CAPS2 diet trial.

Jen-Tsan Chi, Pao-Hwa Lin, Vladimir Tolstikov, Lauren Howard, Emily Y Chen, Valerie Bussberg, Bennett Greenwood, Niven R Narain, Michael A Kiebish, Stephen J Freedland

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Prostate cancer and prostatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Jen-Tsan ChiDepartment of Molecular Genetics and Microbiology, Center for Genomics and Computational Biology, Durham, NC, USA. jentsan.chi@duke.edu.ORCID http://orcid.org/0000-0003-3433-903X
Pao-Hwa LinDepartment of Medicine, Division of Nephrology, Duke University Medical Center, Durham, NC, USA.
Vladimir TolstikovBERG, Framingham, MA, USA.ORCID http://orcid.org/0000-0002-0445-884X
Lauren HowardDuke Cancer Institute, Duke University Medical Center, Durham, NC, USA.ORCID http://orcid.org/0000-0003-3355-4483
Emily Y ChenBERG, Framingham, MA, USA.
Valerie BussbergBERG, Framingham, MA, USA.
Bennett GreenwoodBERG, Framingham, MA, USA.
Niven R NarainBERG, Framingham, MA, USA.
Michael A KiebishBERG, Framingham, MA, USA.
Stephen J FreedlandCenter for Integrated Research in Cancer and Lifestyle, Cedars-Sinai, Los Angeles, CA, USA. stephen.freedland@cshs.org.
Framingham State University · USDuke Medical Center · USCedars-Sinai Medical Center · USCenter for Human Genetics · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSystemic treatments for prostate cancer (PC) have significant side effects. Thus, newer alternatives with fewer side effects are urgently needed. Animal and human studies suggest the therapeutic potential of low carbohydrate diet (LCD) for PC. To test this possibility, Carbohydrate and Prostate Study 2 (CAPS2) trial was conducted in PC patients with biochemical recurrence (BCR) after local treatment to determine the effect of a 6-month LCD intervention vs. usual care control on PC growth as measured by PSA doubling time (PSADT). We previously reported the LCD intervention led to significant weight loss, higher HDL, and lower triglycerides and HbA1c with a suggested longer PSADT. However, the metabolic basis of these effects are unknown.

methodsTo identify the potential metabolic basis of effects of LCD on PSADT, serum metabolomic analysis was performed using baseline, month 3, and month 6 banked sera to identify the metabolites significantly altered by LCD and that correlated with varying PSADT.

resultsLCD increased the serum levels of ketone bodies, glycine and hydroxyisocaproic acid. Reciprocally, LCD reduced the serum levels of alanine, cytidine, asymmetric dimethylarginine (ADMA) and 2-oxobutanoate. As high ADMA level is shown to inhibit nitric oxide (NO) signaling and contribute to various cardiovascular diseases, the ADMA repression under LCD may contribute to the LCD-associated health benefit. Regression analysis of the PSADT revealed a correlation between longer PSADT with higher level of 2-hydroxybutyric acids, ketone bodies, citrate and malate. Longer PSADT was also associated with LCD reduced nicotinamide, fructose-1, 6-biphosphate (FBP) and 2-oxobutanoate.

conclusionThese results suggest a potential association of ketogenesis and TCA metabolites with slower PC growth and conversely glycolysis with faster PC growth. The link of high ketone bodies with longer PSADT supports future studies of ketogenic diets to slow PC growth.

Indexed as

Prostatic NeoplasmsButyratesCarbohydratesDiet, Carbohydrate-RestrictedHumansKetone BodiesMaleProstateProstate-Specific Antigenalpha-ketobutyric acidButyratesCarbohydratesKetone BodiesProstate-Specific Antigen

Identifiers

PMID35338353
OpenAlexW4220786996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.